Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Germline POT1 Variants Can Predispose to a Variety of Hematologic Neoplasms

Tristan L. Lim, BSc, David B. Lieberman, MS, CGC, Adam R. Davis, MD, Ryan Hausler, MS, Ashkan Bigdeli, MS, Yimei Li, PhD, Jacquelyn Powers, MS, LCGC, Regeneron Genetics Center, Shannon A. Carty, MD, Katherine L. Nathanson, MD, Adam Bagg, MD, Elizabeth O. Hexner, MD MSTR, Kara N. Maxwell, MD PhD, Jennifer J.D. Morrissette, PhD, Daria V. Babushok, MD PhD

Blood (2020) 136 (Supplement 1): 2–4.

https://doi.org/10.1182/blood-2020-134160

Published: 2020

Journal Articles

Classical Hodgkin Lymphoma Patients Have an Increased Incidence of Idiopathic Acquired Aplastic Anemia

Taylor Linaburg, BSc, Adam R. Davis, MD, Noelle V. Frey, MD, Daniel J. Landsburg, MD, Stephen J. Schuster, MD, Jakub Svoboda, MD, Yimei Li, PhD, Yuliya Borovskiy, MS, Timothy S. Olson, MD PhD, Adam Bagg, MD, Elizabeth O. Hexner, MD MS, Daria V. Babushok, MD PhD

Blood (2018) 132 (Supplement 1): 5098.

https://doi.org/10.1182/blood-2018-99-110032

Published: 2018

Journal Articles

Limited FISH Testing for MDS-Defining Cytogenetic Abnormalities Rapidly Identifies Patients with Newly Diagnosed AML Eligible for CPX-351

Christine M. McMahon, MD, Nya Nelson, MD PhD, Alex Ganetsky, PharmD, James K. Mangan, MD PhD, Noelle V. Frey, MD, Alexander E. Perl, MD, Mary Ellen Martin, MD, Shannon R. McCurdy, MD, Alison W. Loren, MD MS, Elizabeth O. Hexner, MD MS, Adam Bagg, MD, Jennifer J.D. Morrissette, PhD, Selina Luger, MD

Blood (2018) 132 (Supplement 1): 4785.

https://doi.org/10.1182/blood-2018-99-116415

Published: 2018

Journal Articles

Clinical, Immunophenotypic and Genomic Findings of Acute Undifferentiated Leukemia and Comparison to AML with Minimal Differentiation: A Study from the Bone Marrow Pathology Group

Olga K Weinberg, MD, Robert P. Hasserjian, MD, Ezra Baraban, MD, Chi Young Ok, MD, Julia T Geyer, MD, John KSS Philip, MD, Jason H. Kurzer, MD PhD, Heesun J. Rogers, MD PhD, Valentina Nardi, MD, Richard M. Stone, MD, Jacqueline S. Garcia, Eric D. Hsi, MD, Adam Bagg, MD, Sa A. Wang, MD, Attilio Orazi, MD, Daniel A. Arber, MD

Blood (2018) 132 (Supplement 1): 1491.

https://doi.org/10.1182/blood-2018-99-115198

Published: 2018

Journal Articles

Leukemia Stem Cells Are Characterized By CLEC12A Expression and Chemotherapy Refractoriness That Can be Overcome By Targeting with Chimeric Antigen Receptor T Cells

Saad S Kenderian, MD, Marco Ruella, MD, Olga Shestova, PhD, Michael Klichinsky, PharmD, Miriam Y Kim, MD, Craig Soderquist, MD, Adam Bagg, MD, Reshma Singh, PhD, Celeste Richardson, PhD, Regina M Young, PhD, Carl H June, MD, Saar I. Gill, MD PhD

Blood (2016) 128 (22): 766.

https://doi.org/10.1182/blood.V128.22.766.766

Published: 2016

Journal Articles

Mutational Shift in FLT3 and NPM1-Positive Acute Myeloid Leukemia (AML) Relative to Therapy and Disease Progression

Priya D Velu, MD PhD, Chris C.S. Hsiung, PhD, Kiarash Salafian, Adam Bagg, MD, Jennifer J.D. Morrissette, PhD, Selina Luger, MD

Blood (2016) 128 (22): 2866.

https://doi.org/10.1182/blood.V128.22.2866.2866

Published: 2016

Journal Articles

Next Generation Mutational Profiling Improves Prognostication in Younger Patients with Acute Myeloid Leukemia

Caroline E Sloan, BA, Phyllis A. Gimotty, PhD, Anne Boccuti, MS, Alison R. Sehgal, MD, Jianhua Zhao, PhD, Robert Daber, PhD, Jennifer JD Morrissette, PhD, Selina M. Luger, MD, Adam Bagg, MD, Martin P. Carroll, MD

Blood (2014) 124 (21): 1032.

https://doi.org/10.1182/blood.V124.21.1032.1032

Published: 2014

Journal Articles

Refractory Anemia With Excess Blasts In Transformation (Acute Myeloid Leukemia with 20-29% Blasts) in Older Adults is Less Aggressive Than Acute Myeloid Leukemia With ≥30% Blasts

Blood (2013) 122 (21): 1345.

https://doi.org/10.1182/blood.V122.21.1345.1345

Published: 2013

Journal Articles

A Phase I Clinical Trial Using Eltrombopag in Patients with Acute Myelogenous Leukemia

Noelle V. Frey, MD, Elizabeth O. Hexner, MD, David L Porter, MD, James K. Mangan, MD, PhD, Alison W. Loren, MD, Joseph Hatem, MD, Adam Bagg, MD, Alexander E Perl, MD, Donald E Tsai, MD PhD, Courtney D. DiNardo, MD, Daniel Heitjian, PhD, Selina M. Luger, MD, Martin Carroll, MD

Blood (2012) 120 (21): 3576.

https://doi.org/10.1182/blood.V120.21.3576.3576

Published: 2012

Journal Articles

Clinicopathologic Characterization of Acute Myeloid Leukemia and Myelodysplastic Syndrome with Inv(3)(q21q26.2)/t(3;3)(q21;q26.2) Reveals That Complex Karyotype but Not Blast Percentage Is Associated with Poor Survival; A Bone Marrow Pathology Group Study

Heesun J. Rogers, MD, PhD, James W. Vardiman, MD, John Anastasi, MD, Gordana Raca, MD, PhD, Natasha M Savage, MD, Athena M Cherry, Ph.D., Daniel Arber, MD, Erika Moore, MD, Jennifer JD Morrissette, PhD, Adam Bagg, MD, Yen-Chun Liu, MD, PHD, Susan Mathew, PhD, Attilio Orazi, MD, Pei Lin, MD, Sa A. Wang, MD, Carlos E. Bueso-Ramos, MD, PhD, Kathryn Foucar, MD, Robert P Hasserjian, MD, Eric D. Hsi, MD

Blood (2012) 120 (21): 3847.

https://doi.org/10.1182/blood.V120.21.3847.3847

Published: 2012

Journal Articles

Diverse Histopathologic and Molecular Responses of Acute Myeloid Leukemia to the FLT3 Inhibitor Quizartinib (AC220)

Grant E Nybakken, MD, PhD, Christopher Watt, MD, PhD, Jennifer JD Morrissette, PhD, Adam Bagg, MD, Martin Carroll, MD, Alexander E Perl, MD

Blood (2012) 120 (21): 885.

https://doi.org/10.1182/blood.V120.21.885.885

Published: 2012

Journal Articles

A Robust Xenotransplantation Model for Acute Myeloid Leukemia

Robin L. Perry, MD, Patricia Vanessa Sanchez, PHD, Jean-Emmanuel Sarry, PHD, Alexander Perl, MD, Adam Bagg, MD, Vivianna van Deerlin, Jacklyn Biegel, Gwenn-ael Danet-Desnoyers, Martin Carroll, MD

Blood (2008) 112 (11): 2939.

https://doi.org/10.1182/blood.V112.11.2939.2939

Published: 2008

Journal Articles

A Phase II Trial of Bexarotene, a Retinoid X Receptor Agonist, in Non-M3 Acute Myeloid Leukemia

Donald E. Tsai, MD, PhD, Melissa Potuzak, BS, Anthony Mato, MD, Alison Wakoff Loren, MD, MS, David Porter, MD, Edward A. Stadtmauer, MD, Steven Goldstein, MD, Alexander Perl, MD, Cezary Swider, BS, Adam Bagg, MD, Emile Youssef, MD, PhD, Selina Luger, MD

Blood (2008) 112 (11): 4040.

https://doi.org/10.1182/blood.V112.11.4040.4040

Published: 2008

Journal Articles

A Phase I Trial of Bexarotene, a Retinoid X Receptor Agonist, in non-M3 Acute Myeloid Leukemia: Evidence of Myeloid Differentiation and Clinical Activity.

Donald E. Tsai, MD, PhD, Selina Luger, MD, Allison Kemner, RN, Alison W. Loren, MD, Cezary Swider, PhD, Ami Goradia, MD, Charalambos Andreadis, MD, Richard G. Ghalie, MD, James Thompson, MD, David Porter, MD, Edward A. Stadtmauer, MD, Stephen J. Schuster, MD, Alexander Perl, MD, Adam Bagg, MD, Steven Goldstein, MD, Martin Carroll, MD

Blood (2006) 108 (11): 1955.

https://doi.org/10.1182/blood.V108.11.1955.1955

Published: 2006

Journal Articles

Philadelphia Chromosome (Ph’) Negative, MLL -Rearranged AML Arising in a Patient Treated with Imatinib for CML.

Anna Sechser Perl, MD, Alexander E. Perl, MD, Blaine W. Robinson, PhD, Adam Bagg, MD, David Porter, MD, Ewa Tomczak, Peter C. Nowell, MD, Martin Carroll, MD, Carolyn A. Felix, MD

Blood (2005) 106 (11): 4880.

https://doi.org/10.1182/blood.V106.11.4880.4880

Published: 2005

NARROW

Germline POT1 Variants Can Predispose to a Variety of Hematologic Neoplasms

Classical Hodgkin Lymphoma Patients Have an Increased Incidence of Idiopathic Acquired Aplastic Anemia

Limited FISH Testing for MDS-Defining Cytogenetic Abnormalities Rapidly Identifies Patients with Newly Diagnosed AML Eligible for CPX-351

Clinical, Immunophenotypic and Genomic Findings of Acute Undifferentiated Leukemia and Comparison to AML with Minimal Differentiation: A Study from the Bone Marrow Pathology Group

Leukemia Stem Cells Are Characterized By CLEC12A Expression and Chemotherapy Refractoriness That Can be Overcome By Targeting with Chimeric Antigen Receptor T Cells

Mutational Shift in FLT3 and NPM1-Positive Acute Myeloid Leukemia (AML) Relative to Therapy and Disease Progression

Next Generation Mutational Profiling Improves Prognostication in Younger Patients with Acute Myeloid Leukemia

Refractory Anemia With Excess Blasts In Transformation (Acute Myeloid Leukemia with 20-29% Blasts) in Older Adults is Less Aggressive Than Acute Myeloid Leukemia With ≥30% Blasts

A Phase I Clinical Trial Using Eltrombopag in Patients with Acute Myelogenous Leukemia

Clinicopathologic Characterization of Acute Myeloid Leukemia and Myelodysplastic Syndrome with Inv(3)(q21q26.2)/t(3;3)(q21;q26.2) Reveals That Complex Karyotype but Not Blast Percentage Is Associated with Poor Survival; A Bone Marrow Pathology Group Study

Diverse Histopathologic and Molecular Responses of Acute Myeloid Leukemia to the FLT3 Inhibitor Quizartinib (AC220)

A Robust Xenotransplantation Model for Acute Myeloid Leukemia

A Phase II Trial of Bexarotene, a Retinoid X Receptor Agonist, in Non-M3 Acute Myeloid Leukemia

A Phase I Trial of Bexarotene, a Retinoid X Receptor Agonist, in non-M3 Acute Myeloid Leukemia: Evidence of Myeloid Differentiation and Clinical Activity.

Philadelphia Chromosome (Ph’) Negative, MLL -Rearranged AML Arising in a Patient Treated with Imatinib for CML.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only